MindMaze Therapeutics Annual General Meeting Approves Key Proposals, Elects New Board Members

MindMaze Therapeutics Holding SA (SIX: MMTX) announced the results of its Annual General Meeting held earlier today. Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which did not obtain the required qualified majority.

Shareholders re-elected Walid Hanna, Olaf Blanke and Martin Reiss to the Board of Directors and elected Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors.

In addition, shareholders approved the 2025 Annual Report and financial statements, the appropriation of available earnings, the discharge of the members of the Board of Directors and the Executive Committee, the re-election of Walid Hanna as Chairman of the Board of Directors, the elections to the Nomination and Compensation Committee, the re-election of the Independent Proxy and the statutory auditor, the compensation proposals for the Board of Directors and Executive Committee, and the consultative vote on the 2025 Compensation Report.

Further information on the proposals submitted to shareholders is available in the AGM Invitation. Detailed voting results will be published on the Company’s website later today.

The rejection of the conditional share capital increase is significant as it may impact the company's ability to raise capital through equity issuance without seeking further shareholder approval. However, the strong support for other proposals indicates shareholder confidence in the board's direction, particularly with the addition of Brad Hollinger, a seasoned healthcare executive, and Zach Henderson, the company's CEO, to the board.

MindMaze Therapeutics specializes in scalable precision neurotherapeutics, integrating advanced software, proprietary sensors, and AI-driven data analytics. Its FDA-cleared and CE-marked products address the clinician shortage by providing solutions for stroke, Parkinson's disease, and other neurological disorders. The company's robust R&D pipeline and clinical validation underscore its potential to transform neurorestorative medicine.

Investors and stakeholders can find more information about the company's products and strategy at www.mindmazetherapeutics.com.